Clinical trials: Schizophrenia
Schizophrenia
Real-World Impact of TV-44749 in Adults With Schizophrenia
The main purpose of this trial is to evaluate how TV-44749 (olanzapine long-acting injectable) works in routine clinical practice for adults with schizophrenia.
- Trial name
- RADIANCE (NCT07913100)
- Testing
- TV-44749
- Volunteers
- 1,085 people
- Sponsor
- Teva Branded Pharmaceutical Products R&D LLC
Schizophrenia
A Study to Compare the Pharmacokinetics Profile of DWCZP Tablet 100mg and Clozaril® Tablet 100mg
To evaluate the pharmacokinetics of oral multiple-dose of DWCZP tablet 100mg.
- Trial name
- DWCZP-I-1 (NCT01654601)
- Testing
- DWCZP, Clozaril
- Where
- 5 sites in South Korea
- Volunteers
- 28 people
- Sponsor
- Dong Wha Pharmaceutical Co. Ltd.
Schizophrenia, Schizoaffective Disorders
An Efficacy and Safety Study of Long-acting Risperidone in Participants With Schizophrenia or Schizoaffective Disorders Who Are Receiving Psychiatric Home Care Treatment
The purpose of this study is to evaluate the efficacy and safety of long-acting risperidone microspheres (small uniformly-sized spherical particles, of micrometer dimensions, frequently labeled with radioisotopes or various…
- Trial name
- NCT00526877
- Testing
- Risperidone
- Where
- Taiwan
- Volunteers
- 31 people
- Sponsor
- Johnson & Johnson Taiwan Ltd
Schizophrenia, Paranoid, Schizophrenia, Disorganized
Flexible Dose, Long-term Safety Study of Asenapine for the Treatment of Schizophrenia in Adolescents (P05897)
This study is designed to evaluate whether asenapine, which is approved by the United States Food and Drug Administration (US FDA) for acute treatment of schizophrenia in adults, is generally safe and well tolerated in…
- Conditions
- Schizophrenia, Paranoid, Schizophrenia, Disorganized, Schizophrenia, Undifferentiated
- Trial name
- NCT01190267
- Testing
- asenapine
- Volunteers
- 204 people
- Sponsor
- Organon and Co
Schizophrenia
Evaluation of a Cognitive Adaptive E-treatment in Schizophrenia-diagnosed Adults
This study is a multi-site, double-blind, randomized, controlled clinical trial to assess the safety and effectiveness of plasticity-based, adaptive, computerized-based cognitive remediation treatment versus a computer-based…
- Trial name
- e-CAeSAR (NCT01422902)
- Testing
- Plasticity-based Cognitive Training, Non-plasticity-based Training
- Where
- 2 sites in United States
- Volunteers
- 150 people
- Sponsor
- Posit Science Corporation
Schizophrenia
A Study to Observe Real-life Allocation of Antipsychotics in Acute Inpatient Management of Schizophrenia
RECONNECT-S ALPHA is a multicentre study to observe the management of schizophrenic patients who are hospitalized due to an acutely agitated psychotic episode.
- Trial name
- RECONNECT-S (NCT01394601)
- Where
- 8 sites in Russia
- Volunteers
- 600 people
- Sponsor
- AstraZeneca
Schizophrenia
An Extension Study of Safety and Tolerability of SEP-363856 in Adult Subjects With Schizophrenia
An extension study of safety and tolerability of SEP-363856 in adult subjects with schizophrenia
- Trial name
- NCT02970929
- Testing
- SEP-363856
- Where
- 30 sites in United States, Hungary and 3 more
- Volunteers
- 157 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
First Episode Schizophrenia, Social Function
Effects on Social and Cognition Functions of Blonanserin in First Episode Schizophrenia Patients
This is an open label, multi-center study to explore the effects on social functions of blonanserin in first episode schizophrenia patients
- Conditions
- First Episode Schizophrenia, Social Function, Cognition Function, Blonanserin
- Trial name
- NCT03784222
- Testing
- Blonanserin, MRI and serum BDNF
- Where
- 8 sites in China
- Volunteers
- 102 people, healthy volunteers welcome
- Sponsor
- Marubeni Pharmaceuticals (Suzhou) Co., Ltd.
Schizophrenia
A Study of ALKS 3831 in Adults With Schizophrenia
This is a Phase 2, randomized, placebo-controlled multicenter study, which will be conducted in 2 parts. The study duration for each subject will be approximately 33 weeks and will include 25 study visits.
- Trial name
- NCT01903837
- Testing
- Samidorphan (Low Dose), Samidorphan (Medium Dose), Samidorphan (High Dose)
- Where
- 61 sites in United States, Bulgaria and 1 more
- Volunteers
- 347 people
- Sponsor
- Alkermes, Inc.
Safety and Tolerability of Iloperidone
Tolerability and Pharmacokinetics of Iloperidone in Adolescent Patients
Tolerability, undertstanding of the action of the drug in the body, and understanding the effect of the drug in adolescent patients needing treatment with an antipsychotic medication
- Trial name
- NCT01495169
- Testing
- iloperidone (oral tablet)
- Where
- 10 sites in United States
- Volunteers
- 33 people
- Sponsor
- Vanda Pharmaceuticals
Schizophrenia, Bipolar 1 Disorder
A Trial to Measure the Difference in All-cause Hospitalizations for Participants Who Are Using Abilify MyCite Versus Virtual Matched Controls in Adults With Schizophrenia, Bipolar 1 Disorder, and Major Depressive Disorder
The primary objective of this pragmatic clinical trial (Main Study) was to assess the difference between all-cause hospitalizations in participants using Abilify MyCite versus virtual matched controls.
- Conditions
- Schizophrenia, Bipolar 1 Disorder, Major Depressive Disorder
- Trial name
- NCT03643159
- Testing
- Abilify MyCite - Digital Medicine System, Aripiprazole or other oral antipsychotics
- Where
- 5 sites in United States
- Volunteers
- 2 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Schizophrenia
A Pharmacokinetics Study to Evaluate Safety and Tolerability of JNJ-37822681 in Participants With Stable Schizophrenia
The purpose of this study is to evaluate safety, tolerability and pharmacokinetics (explores what the body does to the drug) of JNJ-37822681 in participants with stable schizophrenia (psychiatric disorder with symptoms of…
- Trial name
- NCT01812642
- Testing
- JNJ-37822681
- Where
- 6 sites in Belgium, Germany and 3 more
- Volunteers
- 33 people
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Schizophrenia
Multiple Ascending Doses of PF-04958242 in Subjects With Stable Schizophrenia
This study aims to assess the safety, tolerability and pharmacokinetics of PF-04958242 in multiple ascending doses in subjects with stable schizophrenia.
- Trial name
- MAD (NCT02332798)
- Testing
- PF-04958242
- Where
- United States
- Volunteers
- 39 people
- Sponsor
- Biogen
Schizophrenia
Pharmacokinetic Study of ABT-126 in Stable Subjects With Schizophrenia
A study to investigate the process by which ABT-126 is absorbed, distributed, metabolized and eliminated by the body of stable schizophrenic volunteers receiving treatment with an atypical antipsychotic.
- Trial name
- NCT01043458
- Testing
- ABT-126
- Where
- 2 sites in United States
- Volunteers
- 16 people
- Sponsor
- Abbott
Schizophrenia
Positron Emission Tomography (PET) Study Investigating Dopamine and Serotonin Receptor Occupancy After Multiple Oral Dosing of Lu AF35700
The purpose of this PET study is to verify the binding of Lu AF35700 after multiple oral dosing at the dopamine and the serotonin receptors in male patients with schizophrenia.
- Trial name
- NCT02333487
- Testing
- Lu AF35700
- Where
- United States
- Volunteers
- 22 people
- Sponsor
- H. Lundbeck A/S
Schizophrenia, Schizoaffective Disorder
A Study to Assess the Effects of RO6889450 (Ralmitaront) in Participants With Schizophrenia or Schizoaffective Disorder and Negative Symptoms
This study investigates the effects of RO6889450 on the negative symptoms associated with schizophrenia and schizoaffective disorder.
- Trial name
- NCT03669640
- Testing
- RO6889450
- Where
- 45 sites in United States, Japan and 2 more
- Volunteers
- 131 people
- Sponsor
- Hoffmann-La Roche
Schizophrenia, Bipolar Disorder
Safety and Tolerability Trial of Lumateperone in Pediatric Patients With Schizophrenia, Bipolar Disorder or Autism Spectrum Disorder
This is a multicenter, global, 26-week, open-label study to assess the safety and tolerability of lumateperone in pediatric patients with schizophrenia, bipolar disorder or autism spectrum disorder.
- Conditions
- Schizophrenia, Bipolar Disorder, Autism Spectrum Disorder
- Trial name
- NCT06229210
- Testing
- Lumateperone
- Where
- 65 sites in United States, Colombia and 1 more
- Volunteers
- 300 people
- Sponsor
- Intra-Cellular Therapies, Inc.
Schizophrenia
A Study of the Efficacy and Safety of Long-acting Injectable Risperidone and Risperidone Tablets in Patients With Schizophrenia
The purpose of this study is to evaluate the effectiveness and safety of risperidone, formulated as a long-acting injectable drug, compared with risperidone tablets in the treatment of patients with schizophrenia.
- Trial name
- NCT00240708
- Testing
- risperidone
- Volunteers
- 205 people
- Sponsor
- Janssen Pharmaceutical K.K.
Schizophrenia
A Study of Aripiprazole Lauroxil or Paliperidone Palmitate for the Treatment of Schizophrenia
This study will evaluate the efficacy of initiating treatment of schizophrenia with ARISTADA INITIO plus 30 mg oral aripiprazole followed by a 2-month dose of AL.
- Trial name
- NCT03345979
- Testing
- Aripiprazole Lauroxil, Paliperidone Palmitate
- Where
- 16 sites in United States
- Volunteers
- 200 people
- Sponsor
- Alkermes, Inc.
Schizophrenia
Relapse Prevention Trial Evaluating KarXT Treatment in Schizophrenia
The purpose of the study is to evaluate the relapse prevention of KarXT in the treatment of participants with Schizophrenia
- Trial name
- NCT07686263
- Testing
- Xanomeline/Trospium Chloride
- Where
- 54 sites in United States, Argentina and 5 more
- Volunteers
- 472 people
- Sponsor
- Karuna Therapeutics, Inc., a Bristol Myers Squibb company
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.